Current topics in microbiology and immunology, Год журнала: 2024, Номер unknown
Опубликована: Янв. 1, 2024
Язык: Английский
Vaccines, Год журнала: 2024, Номер 12(5), С. 459 - 459
Опубликована: Апрель 25, 2024
Understanding the antibody response to SARS-CoV-2, virus responsible for COVID-19, is crucial comprehending disease progression and significance of vaccine therapeutic development. The emergence highly contagious variants poses a significant challenge humoral immunity, underscoring necessity grasping intricacies specific antibodies. This review emphasizes pivotal role antibodies in shaping immune responses their implications diagnosing, preventing, treating SARS-CoV-2 infection. It delves into kinetics characteristics explores current antibody-based diagnostics, discussing strengths, clinical utility, limitations. Furthermore, we underscore potential SARS-CoV-2-specific antibodies, various therapies such as monoclonal polyclonal anti-cytokines, convalescent plasma, hyperimmunoglobulin-based therapies. Moreover, offer insights vaccines, emphasizing neutralizing order confer immunity along with emerging concern (VOCs) circulating Omicron subvariants. We also highlight challenges field, risks antibody-dependent enhancement (ADE) shed light on associated original antigenic sin (OAS) effect long COVID. Overall, this intends provide valuable insights, which are advancing sensitive diagnostic tools, identifying efficient therapeutics, developing effective vaccines combat evolving threat global scale.
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Март 18, 2025
Respiratory viral infections are a major global public health concern, and current antiviral therapies still have limitations. In recent years, research has revealed significant similarities between the immune systems of gut lungs, which interact through complex physiological network known as "gut-lung axis." As one largest organs, gut, along with forms an inter-organ network, strong parallels in innate mechanisms, such activation pattern recognition receptors (PRRs). Furthermore, microbiota influences responses lungs mechanisms systemic transport microbiota-derived metabolites, cell migration, cytokine regulation. Studies shown that dysbiosis can exacerbate severity respiratory may impact efficacy therapies. This review discusses synergistic role gut-lung axis immunity against viruses explores potential strategies for modulating to mitigate infections. Future should focus on drive development novel clinical treatment strategies.
Язык: Английский
Процитировано
0
Molecular Medicine Reports, Год журнала: 2024, Номер 30(2)
Опубликована: Июнь 26, 2024
The coronavirus disease 2019 pandemic due to severe acute respiratory syndrome 2 (SARS‑CoV‑2) seriously affected global public health security. Studies on vaccines, neutralizing antibodies (NAbs) and small molecule antiviral drugs are currently ongoing. In particular, NAbs have emerged as promising therapeutic agents their well‑defined mechanism, high specificity, superior safety profile, ease of large‑scale production simultaneous application for both prevention treatment viral infection. Numerous NAb therapeutics entered the clinical research stages, demonstrating preventive effects. These been used outbreak control under urgent authorization processes. present review summarizes molecular targets SARS‑CoV‑2‑associated screening identification techniques development. Moreover, current shortcomings challenges that persist with use discussed. aim is offer a reference development any future emergent infectious diseases, including SARS‑CoV‑2.
Язык: Английский
Процитировано
2
Transplant Infectious Disease, Год журнала: 2024, Номер 26(4)
Опубликована: Июнь 27, 2024
Hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell therapy (CAR-T) recipients are at higher risk of serious complications COVID-19 infection than the general population. Though there is evidence that monoclonal antibodies (MCA) against reduce death hospitalization in population, data regarding their efficacy HSCT CAR-T remains scarce.
Язык: Английский
Процитировано
1
Vaccines, Год журнала: 2024, Номер 12(11), С. 1220 - 1220
Опубликована: Окт. 27, 2024
Emerging viral diseases, including seasonal illnesses and pandemics, pose significant global public health risks. Respiratory viruses, particularly coronaviruses influenza are associated with high morbidity mortality, imposing substantial socioeconomic burdens. This review focuses on the current landscape of respiratory SARS-CoV-2, their antiviral treatments. It also discusses potential for pandemics development new vaccines therapies, drawing lessons from past outbreaks to inform future strategies managing threats.
Язык: Английский
Процитировано
1
Current topics in microbiology and immunology, Год журнала: 2024, Номер unknown
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0